Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chastened Innate Returns Lumoxiti Rights To AZ

Struggled To Commercialize Hairy Cell Leukemia Drug

Executive Summary

The French firm gave back the rights to Lumoxiti on the same day the drug got a thumbs up from the CHMP after struggling to market the rare leukemia drug in the US.

You may also be interested in...



AstraZeneca Pulls Plug On Lumoxiti Due To Low Uptake

Signs of trouble were already emerging in 2020 when Innate backed out of a co-commercialization pact. AstraZeneca plans to discontinue the hairy cell leukemia ADC in July.

AstraZeneca Finds Two More Potential Partners For Imfinzi

Adding oleclumab and monalizumab to the PD-L1 inhibitor improved PFS, while another study showed improved real-world outcomes.

Deal Watch: GSK Makes $85m Wager On Surface’s Preclinical NK Cell Therapy

Although SRF813 isn’t likely to reach the clinic until 2021, GSK likes cell therapy’s monotherapy and combination potential. Lilly bids $880m to acquire neurodegenerative cell therapy firm Prevail.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC143485

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel